
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39300177
72694
10.1038/s41598-024-72694-4
Article
Unraveling the role of gut microbiota by fecal microbiota transplantation in rat model of kidney stone disease
Hunthai Sittiphong 1
Usawachintachit Manint 2
Taweevisit Mana 3
Srisa-Art Monpichar 4
Anegkamol Weerapat 1
Tosukhowong Piyaratana 1
Rattanachaisit Pakkapon 1
Chuaypen Natthaya 1
Dissayabutra Thasinas thasinas@chula.md

1
1 https://ror.org/028wp3y58 grid.7922.e 0000 0001 0244 7875 Metabolic Disease in Gastrointestinal and Urinary System Research Unit, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330 Thailand
2 https://ror.org/028wp3y58 grid.7922.e 0000 0001 0244 7875 Division of Urology, Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330 Thailand
3 https://ror.org/028wp3y58 grid.7922.e 0000 0001 0244 7875 Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330 Thailand
4 https://ror.org/028wp3y58 grid.7922.e 0000 0001 0244 7875 Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, 10330 Thailand
20 9 2024
20 9 2024
2024
14 2192420 3 2024
10 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Emerging research on the microbiome highlights the significant role of gut health in the development of kidney stones, indicating that an imbalance in gut bacteria or dysbiosis can influence the formation of stones by altering oxalate metabolism and urinary metabolite profiles. In particular, the overabundance of specific bacteria such as Enterococcus and Oxalobacter spp., which are known to affect oxalate absorption, is observed in patients with urolithiasis. This study investigates the effects of gut dysbiosis on urolithiasis through fecal microbiota transplantation (FMT) from patients to rats and its impact on urinary mineral excretion and stone formation. Fecal samples from eight patients with calcium oxalate stones and ten healthy volunteers were collected to assess the gut microbiome. These samples were then transplanted to antibiotic-pretreated Wistar rats for a duration of four weeks. After transplantation, we evaluated changes in the fecal gut microbiome profile, urinary mineral excretion rates, and expression levels of intestinal zonula occluden-1 (ZO-1), SLC26A6 and renal NF-κB. In humans, patients with urolithiasis exhibited increased urinary calcium and oxalate levels, along with decreased citrate excretion and increased urinary supersaturation index. The fecal microbiota showed a notable abundance of Bacteroidota. In rodents, urolithiasis-FMT rats showed urinary disturbances similar to patients, including elevated pH, oxalate level, and supersaturation index, despite negative renal pathology. In addition, a slight elevation in the expression of renal NF-κB, a significant intestinal SLC26A6, and a reduction in ZO-1 expression were observed. The gut microbiome of urolithiasis-FMT rats showed an increased abundance of Bacteroidota, particularly Muribaculaceae, compared to their healthy FMT counterparts. In conclusion, the consistent overabundance of Bacteroidota in both urolithiasis patients and urolithiasis-FMT rats is related to altered intestinal barrier function, hyperoxaluria, and renal inflammation. These findings suggest that gut dysbiosis, characterized by an overgrowth of Bacteroidota, plays a crucial role in the pathogenesis of calcium oxalate urolithiasis, underscoring the potential of targeting the gut microbiota as a therapeutic strategy.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-72694-4.

Keywords

Urolithiasis
Gut microbiota
Fecal microbiota transplantation
Oxalate
Gut leakage
Subject terms

Biochemistry
Microbiology
Biomarkers
Urology
the Program Management Unit for Human Resources and Institutional Development, Research, and Innovation (PMU-B)B36G660010 Dissayabutra Thasinas Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University, grant numberRA65/045 Dissayabutra Thasinas issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Urolithiasis, a major global health issue, affects a wide range of populations regardless of demographics or geography1, with an estimated 10–15% of the global population experiencing this condition at least once in their life2. The origins of urolithiasis are complex and multifaceted, involving a combination of genetic predispositions, diet practices, fluid consumption, and underlying health conditions such as obesity, diabetes, and hypertension. Stone formation is mainly due to the supersaturation of the urine with minerals like calcium, oxalate, phosphate, urate, and cystine3, a process influenced by urinary pH and the balance between crystallisation inhibitors and promoters.

Recent breakthroughs in microbiome research have highlighted the significant role of the gut microbiota in the pathogenesis of kidney stones, marking a pivotal shift in our understanding and management strategies for urolithiasis. Emerging studies suggest that gut dysbiosis, or the imbalance of the gut microbiota, could substantially impact the risk and development of kidney stones through mechanisms such as modulation of urinary metabolites, changes in intestinal oxalate metabolism, and systemic inflammatory response4. In particular, bacteria such as Oxalobacter spp., especially O. formigenes, known for their ability to degrade oxalate, could reduce oxalate absorption and lower the risk of stone formation5,6. However, recent evidence suggests that supplementing with O. formigenes may not effectively lower urinary oxalate levels or prevent stone formation7–9. Furthermore, a phase III clinical trial focussing on children with primary hyperoxaluria found no significant change in plasma oxalate levels after a year of treatment with O. formigenes, further questioned the efficacy of such intervention10.

Rather than Oxalobacter, other gut microbiota can exert wider effects that contribute to stone pathogenesis, including modulation of the host’s immune system, intestinal permeability, and inflammatory pathways. Gut bacteria such as Lactobacillus, Bifidobacterium, Eubacterium, and Enterococcus faecalis have been implicated in the processes of oxalate absorption and stone formation11. Previous studies revealed the oxalate degrading capacity of B. animalis subsp. Lactis, E. lentum, E. faecalis, B. lactis and L. plantarum in vitro, particularly due to the presence of the oxalate decarboxylase gene12.

In patients with stone disease, patterns of gut dysbiosis, characterized by varying abundances of specific microbial genera, have been identified. Increased abundance of Bacteroidota, Escherichia_Shigella and less abundance of Prevotella_9 commonly present in patients with urolithiasis13,14. These anomalies suggest a complex interplay between gut microbial composition and urolithiasis, which is not limited to exclusive degradation of oxalates. Interestingly, fecal transplantation studies, such as the one in which the microbiota of Zucker lean mice were transferred to germ-free mice, have shown potential to reduce urinary excretion of calcium, oxalate, and alter intestinal pH levels, pointing towards gut dysbiosis as a contributing factor to urolithiasis15. Despite the accumulation of evidence of an association between the gut microbiota and stone formation, the causality of this relationship remains to be fully elucidated.

The study is designed to investigate the gut microbial communities in patients with urolithiasis compared to healthy individuals. To further elucidate the pathophysiology of gut dysbiosis in calcium oxalate lithogenesis, we transplanted the fecal microbiota of urolithiasis patients into antibiotic-pretreated rats and contrasted these results with volunteer-FMT rats. We seek to uncover the specific role that gut dysbiosis plays in altering the intestinal gut barrier, urinary mineral excretion patterns, and renal inflammation.

Materials and methods

This research included cross-sectional studies on the human microbiome and experimental studies in animals.

Ethical declaration

The study involved the collection of urine and stool samples using anaerobic methods and was approved by the Institutional Review Board, Faculty of Medicine, Chulalongkorn University, Thailand (COA No. 0995/2022). The experiments were performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants. The animal study protocol was approved by the Chulalongkorn University Animal Care and Use Committee of the Faculty of Medicine, Chulalongkorn University, Thailand (CU-ACUC No. 004/2565). All experiments were performed according to the IACUC and ARRIVE guidelines and regulations.

Human participants

In this study, eight patients with calcium oxalate urolithiasis received surgical treatment at the Chulalongkorn Hospital Urological Surgery Unit and ten healthy participants were included. Urine samples from the morning, first voiding spot urine samples were obtained to assess creatinine, calcium, and magnesium levels using electrochemiluminescence (COBAS C6000, Roche, USA) and to measure oxalate and citrate by capillary electrophoresis (P/ACETM MDQ, Beckman Coulter, USA). Fecal samples were also gathered using the AnaeroPouch -Anaero system (Mitsubishi Gas Chemical Co., Japan), from which a portion was treated to isolate DNA with a DNA/RNA shield (Zymo Research, USA) for subsequent sequencing.

16 S rRNA amplicon sequencing and analysis

To sequence 16s rRNA, the hypervariable V4 regions of the 16 S rRNA genes were amplified from DNA samples using 515 F (5′GTGCCAGCMGCCGCGGTAA 3′) and 806R (5′GGACTACHVGGGTWTCTAAT3′) primers and 2X KAPA hot start ready mix. The PCR conditions included an initial denaturation at 94 °C for 3 min, followed by 25 cycles of 98 °C for 20 s, 55 °C for 30 s 72 °C for 30 s, and a final extension step at 72 °C for 5 min. The 16 S amplicons were purified using AMPure XP beads and indexed using the Nextera XT index kit, followed by 8 cycles of the aforementioned PCR condition. Finally, the PCR products were cleaned and pooled for cluster generation and 250 bp paired-end read sequencing on the Illumina® MiSeq (Mod Gut Co., Ltd., Bangkok, Thailand).

The quality of the raw data was assessed using FastQC (v0.11.8) and MultiQC (v1.7). QIIME2 (version 2022.2) was applied to perform microbiome analysis. The adapter and preceding bases were trimmed at the 5′ end of the reads using the q2-cutadapt plugin. Reads with expected errors (maxEE) higher than 3.0 were discarded, paired end reads were merged with an overlap of 25 nucleotides between forward and reverse reads, and chimeric sequences were filtered using the q2-dada2 plugin.

The taxonomic classifier was trained using the V4 sequence based on the naive Bayes classifier model using the q2-feature classifier plugin. Amplicon sequence variants (ASVs) were assigned for taxonomy based on the reference sequences of Sklearn method against the SILVA (version 138.1) 99% operational taxonomic units (OTUs). The unassigned mitochondria and chloroplast sequences were removed using the q2-taxa plugin. Calculations of the rarefaction curve, richness index diversity index, and Principal coordinate analysis (PCoA) and permutational multivariate analysis of variance (PERMANOVA) based on the Bray-Curtis distance were generated using the vegan package of R4.0.3.

Human urinary supersaturation index was calculated using the following equation16:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{\text{A}\text{P}}_{\text{C}\text{a}\text{O}\text{x}}=\:\frac{2.7\:\bullet\:{\:\text{C}\text{a}\text{l}\text{c}\text{i}\text{u}\text{m}}^{0.84}\:\bullet\:\:\text{O}\text{x}\text{a}\text{l}\text{a}\text{t}\text{e}}{{\text{C}\text{i}\text{t}\text{r}\text{a}\text{t}\text{e}}^{0.22}\:\bullet\:\:{\text{M}\text{a}\text{g}\text{n}\text{e}\text{s}\text{i}\text{u}\text{m}}^{0.12\:}\bullet\:\:{\text{V}\text{o}\text{l}\text{u}\text{m}\text{e}}^{1.03}}$$\end{document}

APCaOx: Approximate Estimation of the Ion Activity Product of calcium oxalate.

Fecal microbiota transplantation (FMT) in Wistar rats

Three-week-old male Wistar rats, sourced from Nomura Siam Co. LTD in Thailand underwent a one-week acclimatization period before being housed in normal showbox cages in the Animal Lab at the Faculty of Medicine, Chulalongkorn University. The laboratory environment was meticulously controlled, maintaining a temperature of 25 °C, relative humidity between 30 and 50%, and a consistent 12-hour light/dark cycle. Throughout the study, rats had unrestricted access to food and water. To initiate partial eradication of the gut microbiota, their drinking water was supplemented with a cocktail of antibiotics (ampicillin 1 g/L, ciprofloxacin 1 g/L metronidazole 1 g/L, and vancomycin 0.5 g/L) for a duration of 7 days17. Following this phase, the rats were organized into two groups, each comprising six individuals. From week 0, systematic collections of blood, urine, and fecal samples were carried out for further analysis.

To create the fecal microbiota extract, we pooled 3 g of each fecal sample from urolithiasis into a urolithiasis-FMT mixture, and each sample from the volunteer into a healthy mixture of FMT, separately. Each sample was dissolved in 45 mL of 0.9% sodium chloride solution. The samples were then vigorously vortexed for 10 s and meticulously filtered three times through gauze, all under strict anaerobic conditions to preserve microbial integrity. Following filtration, the mixtures were centrifuged at 6,000 g for 15 min, allowing the collection of the clear supernatant18. The supernatant was then carefully combined with 20% glycerol, forming a protective medium for the microbial content, and subsequently stored at -20 °C for future analyses19.

During the experimental phase, the control group received an FMT solution derived from healthy individuals, while the urolithiasis group was administered FMT derived from patients with kidney stones. Each administration of FMT involved a 400 µL volume, administered by gavage twice weekly for a duration of four weeks. To simulate a high oxalate intake, sodium oxalate was incorporated into the drinking water of both groups at a concentration of 1% (w/w).

At the end of the experiment, the rats were placed in a metabolic cage for 24 h to collect the urine sample. Isoflurane was used as an anesthetic drug for blood collection from the retrobulbar vein before euthanasia using CO2 inhalation, and intestinal fecal samples were harvested immediately after euthanization. Subsequently, the intestines and jejunum were meticulously harvested for further analysis. In our biochemical assessment, blood samples were analysed for calcium and magnesium levels, while urine samples were evaluated for concentrations of calcium, magnesium, oxalate, citrate, creatinine and urinary supersaturation index.

Urinary supersaturation index was calculated using the following equation16:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:{\text{A}\text{P}}_{\text{C}\text{a}\text{O}\text{x}}=\:\frac{4067\:\bullet\:\:{\text{C}\text{a}\text{l}\text{c}\text{i}\text{u}\text{m}}^{0.93}\:\bullet\:\:{\text{O}\text{x}\text{a}\text{l}\text{a}\text{t}\text{e}}^{0.96}}{{(\text{C}\text{i}\text{t}\text{r}\text{a}\text{t}\text{e}+0.015)}^{0.60}\bullet\:{\text{M}\text{a}\text{g}\text{n}\text{e}\text{s}\text{i}\text{u}\text{m}}^{0.55}\bullet\:{\text{V}\text{o}\text{l}\text{u}\text{m}\text{e}}^{0.99}}$$\end{document}

For histological and genetic analyses, the intestines and kidneys were sectioned into two parts. The first section was forwarded to the Department of Pathology of the Faculty of Medicine, Chulalongkorn University, for detailed histopathological examination. The second section was RNA extraction using TRIzol LS reagent to facilitate RT-PCR assays. These assays were specifically designed to quantify the expression levels of intestinal zonula occluden-1 (ZO-1) and the oxalate transporter, Solute Carrier Family 26 Member 6 (SLC26A6), which offers insight into the molecular impact of our experimental interventions.

Fecal microbiota analyses

DNA extractions from bacterial feces were performed in both human and animal models using the Quick-DNATM Fecal/Soil Microbe Microprep Kit. The DNA extract was forwarded to ModGut Co., Ltd. (Thailand) for a comprehensive analysis of the fecal microbiota present in participants and animal models alike. To analyze the biological data of the 16 S rRNA (V3-V4 region), we employed QIIME software (Quantitative Insights into Microbial Ecology) software, a powerful tool for microbial community analysis. Sequences had been classified into various operational taxonomic units (OTUs), providing a detailed framework for understanding the diversity of microbials. To evaluate the diversity within the microbial population, we calculated the relative abundance using Shannon’s index.

Histopathology analyses

Kidney and jejunum samples were meticulously sectioned transversely, then carefully placed on cassettes and submerged in 10% neutral buffer formalin to ensure their preservation. The Department of Pathology of the Faculty of Medicine, Chulalongkorn University carried out the tissue staining process. The jejunum sections were stained with hematoxylin and eosin (H&E) and further analyzed through immunohistochemistry to detect ZO-1 expression.

For the assessment of histopathological changes in the kidneys of animal models, crystal deposits were examined in three distinct regions: the cortex, the cortical medullary junction, and the tip of the papillary21. This examination was conducted using a polarizing microscope at a magnification of X400. In a similar vein, jejunum sections were scrutinized under a microscope to evaluate ZO-1 staining, providing insight into the integrity of the intestinal barrier22. A pathologist was responsible for the scoring of these observations, ensuring a thorough and expert analysis of the histopathological features presented in both the kidney and intestinal samples of animal models.

Gene expression

Gene expression levels were accurately quantified using the quantitative polymerase chain reaction (qPCR) technique, employing the state-of-the-art QuantStudioTM 5 Real-Time PCR System. Complementary DNA (cDNA), synthesized from jejunum samples using the RevertAid First Strand cDNA Synthesis Kit, served as the template for measuring the expression of key genes: Zonula occluden-1 (ZO-1)23, Solute carrier family 26, Member 6 (SLC26A6)24 in the jejunum and the Nuclear Factor Kappa B subunit 1 gene (NF-kB)25 in the kidney. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as the reference gene23. CT values obtained from qPCR were utilized to calculate the gene expression levels using the 2−ΔΔCq method. This analysis could provide information on the relative expression levels of target genes compared to the housekeeping gene.

Statistical analysis

Data from research participants were analyzed using unpaired t-tests to compare general information, such as age. The chi-square test was used to analyze non-numeric data, such as gender. For the data from experimental animals, multiple repeated measures ANOVA with Bonferroni post hoc analysis was used to compare changes before and after the various values of the parameters. Additionally, Student’s t-tests were conducted to compare groups of rats, and paired t-tests were employed to analyze data with normal distributed, paired measurements, while Wilcoxon matched pairs signed rank test was used to evaluate unequal distributed data such as urinary mineral excretion. In the gut microbiome analysis, the most abundant taxa at the phylum and genus levels were demonstrated at the ASV level. The Mann Whitney test was used to evaluate the relative bacterial species. The Kruskal-Wallis test was employed for alpha and beta diversity analysis. Statistical analyses were performed using SPSS version 23.0 (IBM Statistics, USA) and GraphPad Prism version 9.4 (DotMatics, USA). The statistically significant was obtained when p < 0.05. The Chi-square test was utilised to analyze the tissue results.

Results

Human urinary profile

Our study compared demographic and urinary biochemical parameters between control participants (n = 10) and people diagnosed with urolithiasis (n = 8) (Table 1). Demographic data, including gender distribution, age, and body mass index (BMI), did not show significant differences between the two groups. Participants with diabetes mellitus and hypertension were present in the urolithiasis group.

Table 1 Epidemiological data and urinary parameters of participants.

Factors	Control
(n = 10)	Urolithiasis
(n = 8)	P-value	
Participants information			
Gender (Male/Female)	3/7	2/6	0.060	
Age (years)	43.5 ± 11.8	48.9 ± 14.6	0.449	
Body mass index (kg/m2)	24.826 ± 3.506	25.288 ± 3.526	0.785	
Diabetes mellitus (persons)	0	1		
Hypertension (persons)	0	2		
Urinary parameters	
Ca/Cr (mg/gCr)	64.9 ± 43.7	257.3 ± 264.2*	0.043	
Ox/Cr (mg/gCr)	20.9 ± 8.9	40.5 ± 11.7*	0.005	
Cit/Cr (mg/gCr)	662.8 ± 266.1	355.2 ± 237.2*	0.031	
Mg/Cr (mg/gCr)	174.7 ± 229.1	86.7 ± 53.8	0.573	
Urine pH	6.8 ± 0.6	6.3 ± 0.7	0.097	
Urine supersaturation index	25.7 ± 26.5	98.8 ± 102.2*	0.027	
Data expressed in mean ± SD, Ca: calcium, Cr: creatinine, Ox: oxalate, Cit: citrate, Mg: magnesium* p < 0.05 compared to healthy control.

The urine biochemical analyses revealed significant disparities in several key parameters associated with the risk of stone. The calcium-to-creatinine ratio (Ca/Cr) and oxalate-to-creatinine ratio (Ox/Cr) were significantly elevated in the urolithiasis group compared to the control group. On the contrary, the citrate-to-creatinine ratio (Cit/Cr) was significantly reduced in the urolithiasis group. There was no significant difference in the magnesium-to-creatinine ratio (Mg/Cr) between the two groups. The pH tended to be lower in the urolithiasis group, although this did not reach statistical significance (P = 0.097). In particular, the urine supersaturation index, a marker of the risk of stone formation, was significantly higher in the urolithiasis group (P = 0.027).

Human microbiome study

There was no difference in alpha diversity between both groups, as shown in the Shannon index, richness, and evenness (Fig. 1). Similarly, beta-diversity did not show distinctive dissimilarity between healthy volunteers and urolithiasis patients.

Fig. 1 The alpha and beta diversity of the fecal microbiota compared between healthy volunteers with human urolithiasis patients. No significant differences were detected in alpha-diversity (A) Shannon index, (B) richness, and (C) Evenness and (D) beta-diversity by PCoA based on Bray-Curtis dissimilarity index.

For taxonomic analysis, the relative abundance of bacteria at the phylum levels is shown in Fig. 2. The increased relative abundance of Bacteroidota was found in patients with urolithiasis, while the abundance of other bacteria was not significantly different.

Fig. 2 Human fecal microbiome profile of healthy volunteer and urolithiasis patients. (A) The relative abundance of the most abundant microbiota in each subject. (B) Relative abundance of the human fecal microbiota in the phylum. *p < 0.05.

Comparative analysis of the human fecal microbiota, stratified by phylum, identified Firmicutes as the most prevalent phylum in both healthy control and urolithiasis cohorts. A noticeable decline in the relative abundance of the Actinobacteriota and Proteobacteria phyla was observed among individuals with urolithiasis. Furthermore, Verrucomicrobiota and Desulfobacterota phyla were consistently present in the fecal samples of both groups. Interestingly, at the genus level, Bifidobacterium and Oscillospiraceae UCG002 were significantly depleted in the urolithiasis group compared to the healthy controls (supplementary Table S1).

Urinary parameters of rats transplanted with the fecal microbiota

Rats that received fecal microbiome transplants from healthy individuals did not show statistically significant changes in urinary excretion rates of calcium, oxalate and magnesium, nor in urine pH and urinary supersaturation index. The only change observed was a reduction in urinary citrate excretion, as illustrated in Fig. 3. On the contrary, rats that were transplanted with the fecal microbiota of patients with urolithiasis experienced an increase in both urine pH and urinary oxalate excretion rates, along with a decrease in urinary magnesium and citrate. In particular, the urinary supersaturation index showed a significant increase in these rats after FMT. Furthermore, the post-transplant urinary oxalate excretion rate in rats with the urolithiasis-derived microbiota exceeded that of their control counterparts.

Fig. 3 The urinary parameters of the rats at week 0 and week 4 after fecal microbiota transplantation. Data were normalized by creatinine and presented as median ± SD. Statistical significance was denoted as *p < 0.05, **p < 0.005, and ***p < 0.001, compared to the control group.

Renal pathology and gene expression in animal tissues

Renal histopathological analysis revealed no evidence of tubular injury or calcium oxalate crystal deposition in either group, as shown in Fig. 4A. Expression of NF-κB mRNA in the renal tissues of urolithiasis-FMT rats appeared to be nonstatistically significantly higher than healthy FMT rats, although non-statistical significance was obtained (Fig. 4B). In the intestines of FMT rats, there was an observed overexpression of SLC26A6 mRNA (Fig. 4C). Furthermore, a down-regulation of ZO-1 protein expression detected by immunohistochemistry (Fig. 4D and E), and mRNA expression (Fig. 4F) were observed when compared to their control counterparts.

Fig. 4 The study of histopathology and gene expression in animal tissues. (A) Histopathological examination of the kidney under a polarized light microscope, categorized into control rats (a, c, and e) and urolithiasis rats (b, d, and f). (B) Analysis of NF-kB mRNA expression in kidney tissue. (C) Analysis of SLC26A6 mRNA expression in jejunum tissue. (D) Histopathological examination of the jejunum using immunohistochemistry against ZO-1 (ZO-1 stained orange or brown, cytoplasm stained in blue) (E) Analysis of jejunal ZO-1 protein expression, and (F) Analysis of jejunal ZO-1 mRNA expression. Statistical significance was denoted as *p < 0.05 compared to the control group.

Animal microbiome study

Alpha diversity, measured using the Shannon index for control rats and urolithiasis rats after four weeks of FMT, showed an elevation in Shannon entropy for both groups. This suggests an increased richness and evenness of the bacterial population. However, a closer examination of alpha diversity at week 4 revealed that urolithiasis rats had a significantly lower relative abundance compared to control rats (p < 0.05). The comparison of beta diversity between pre- and post-FMT samples unveiled a statistically significant shift (p < 0.01), with an F value of 42.001 and R-squared of 0.683, indicative of significant compositional changes in the gut microbiota after FMT, as illustrated in Fig. 5A.

Phylum-level analysis of the pre-transplant fecal microbiota identified Firmicutes as the most populous phylum, as seen in Fig. 5B. In post-FMT, both groups exhibited a decrease in the relative abundance of Firmicutes compared to the initial measurements at week 0. At week 4, no significant difference in the relative abundance of Firmicutes (p = 0.423), but elevations of Bacteroidota were observed in urolithiasis rats (p = 0.015). However, a noteworthy decrease in Euryarchaeota (p = 0.025), coupled with increases in Desulfobacterota and Cyanobacteria, was observed in urolithiasis rats (p = 0.010 and 0.037, respectively).

Fig. 5 The gut microbiome results in rats transplanted with the fecal microbiota. (A) alpha and beta diversity of pre- and post-fecal microbiota transplantation rats in each group; (B) The most abundant intestinal microbiota in each group was demonstrated in phylum and genus levels.

At the genus level, urolithiasis rats showed the increase in an abundance of Muribaculaceae (Phylum Bacteroidota) along with a decrease in Prevotellaceae (Phylum Bacteroidota), Methanosphaera (Phylum Euryarchaeota), Roseburia, Colidextribacter (Phylum Bacillota) and Eubacterium siraeum.

Discussion

Patients with urolithiasis in our study exhibited several known risk factors for stone formation, such as increased urinary excretion of calcium and oxalate coupled with reduced urinary citrate excretion. In particular, the urinary supersaturation index was significantly elevated, approximately 3.8 times higher in stones patients compared with healthy individuals, underscoring it as a critical risk factor for urolithiasis. Echoing previous research, our investigation also identified gut dysbiosis in patients with urolithiasis, characterized primarily by an increased abundance of Bacteroidota. This contrasts with previous reports that did not find significant changes in the Escherichia_Shigella or Prevotella14,15. Consistent increase in Bacteroidota abundance emerges as a hallmark of gut dysbiosis associated with urolithiasis.

Furthermore, we extended these findings to an animal model, where rats receiving fecal microbiota transplants from patients with urolithiasis also showed a higher prevalence of Muribaculaceae of the phylum Bacteriodota compared to those receiving transplants from healthy controls. This parallel increase in Bacteroidota suggests that fecal microbiota transplantation was effective in replicating the gut dysbiosis observed in human urolithiasis within the rat model. Our results support that gut dysbiosis could play a contributing role in the pathogenesis of urolithiasis and they affirm the potential of FMT as a tool to model disease-associated microbiota alterations in experimental settings.

In our study, urolithiasis-FMT rats later developed gut dysbiosis, exhibiting specific disorders that are recognized as risk factors for calcium oxalate urolithiasis. These included elevated urinary oxalate levels, decreased urinary magnesium, increased urine pH26, and elevation of the urinary supersaturation index that was approximately three times higher compared to controls. These findings indicate the substantial influence of gut dysbiosis on the pathogenesis of urolithiasis, particularly implicating alterations in oxalate metabolism.

Oxalate in the body originates from two primary sources: dietary intake and endogenous synthesis. In the endogenous pathway, oxalate is a by-product of the metabolism of various biomolecules, including ascorbic acid, L-hydroxy-lysine, and glyoxalate27. In our rat model, we maintained a consistent diet across the board, which should standardize the production of endogenous oxalate. However, the absorption of exogenous or dietary oxalate may differ significantly due to gut dysbiosis.

Gut dysbiosis is well established to lead to increased intestinal epithelial permeability28, a process often linked to down-regulation of tight junction proteins, pro-inflammatory responses, endotoxin production, and bacterial translocation29. Gram-negative bacteria proliferation in the gut, particularly Bacteroides spp., which constitutes the largest gram-negative phylum in the gut microbiota, correlates with increased endotoxins, especially lipopolysaccharides (LPS), thereby exacerbating gut permeability30. Although some Bacteroides species produce less endotoxin or even inhibiting toxin production, the whole Bacteroidota phylum generates more endotoxin relative to other Gram-positive bacteria, such as Firmicutes31,32. In this context, we hypothesized that the gut dysbiosis observed in urolithiasis could lead to compromised integrity of the intestinal barrier, enhancing the paracellular absorption of both LPS and oxalate. Our findings confirm this hypothesis, demonstrating that rats receiving FMT from urolithiasis patients not only exhibited gut dysbiosis but also showed reduced expression of the intestinal tight junction protein ZO-1, indicative of potential gut leakage and could induce renal inflammation.

The chloride/oxalate transporter SLC26A6 is highly expressed in the renal epithelium, the apical regions of the salivary glands, and the villi of the small intestine, which spans from the duodenum through the jejunum and ileum, yet it is markedly reduced in the large intestine33. The process of oxalate transport in the intestine is bidirectional, involving net absorption—primarily through transcellular (through the SLC26A1 and SLC26A3 transporters) and paracellular routes, and secretion, which is regulated by the SLC26A6 and, to a lesser extent, the SLC26A2 transporters34. The role of intestinal SLC26A6 is pivotal in facilitating the clearance of serum oxalate, thus minimizing the oxalate load in body35. Evidence from previous research indicates that wild-type mice with intact intestinal SLC26A6 expression exhibit resistance to urolithiasis36, while SLC26A6 knockout (KO) mice are prone to hyperoxalemia, hyperoxaluria, and kidney stone37. The expression of SLC26A6 is modulated by various factors, including inflammation, microRNAs, and metabolites. A study by Liu Y. in 2021 highlighted that short-chain fatty acids such as acetate and propionate improve intestinal SLC26A6 and reduced intestinal oxalate absorption24. Recent research has shown that FMT rats with increased Muribaculaceae, Lactobacillus, and Bifidobacterium exhibited significantly lower urinary oxalate excretion and reduced calcium oxalate crystal deposition38.

Our findings align with these observations, showing an up-regulation of intestinal SLC26A6 expression. This up-regulation can be attributed to a high influx of oxalate or the influence of an increased abundance of Bacteroidota, particularly Muribaculaceae, a prominent propionate-producing bacterial family39,40. The increase in the intestinal oxalate-secreting transporter SLC26A6 could represent an adaptive mechanism to mitigate elevated serum oxalate levels resulting from enhanced intestinal absorption and intestinal leakage, thereby reducing the overall burden of oxalate burden in the body.

The limitations of this study are including the use of spot urine in the evaluation of urinary mineral excretion in volunteers and urolithiasis patients, which was less accurate, as the excretion of urinary calcium, oxalate, and citrate has a circadian pattern. We had minimized the fluctuation by collecting the morning first voiding urine from the participants. Secondly, germ-free rats are a better model for the microbiota transplantation model than antibiotic knockout rats. Residual native gut bacteria can potentially affect the proliferation and function of the transplanted microbiota. Lastly, we could not directly measure intestinal oxalate absorption due to free access to food and water from the animals, and the fecal oxalate content was not accurately measured, since the defecating interval of the rats was unexpectable.

Conclusion

Our study reveals a notable link between the gut microbiota, dysbiosis, leaky gut syndrome, and urolithiasis. In particular, an increased abundance of Bacteroidota in patients with calcium oxalate stone disease is considered a risk factor for urolithiasis. This is because intestinal dysbiosis causes gut hyperpermeability, which stimulates intestinal oxalate absorption. This leads to hyperoxaluria and increased urinary supersaturation (Fig. 6). Furthermore, up-regulation of the SLC26A6 transporter in the context of urolithiasis underscores potential compensatory responses to increased oxalate levels, possibly influenced by the prevalence of Muribaculaceae. Addressing intestinal dysbiosis emerges as a strategic consideration to mitigate urolithiasis in high-risk individuals.

Fig. 6 The hypothesis of gut Bacteroidota overabundance in calcium oxalate urolithiasis, created with BioRender.com.

Declaration of AI and AI-assisted technologies in the writing process

In the development of this manuscript, the author employed Writefull for grammatical corrections, and BioRender.com to create a figure. Following the utilization of this tool, the author meticulously reviewed and adjusted the content where necessary, assuming complete accountability for the final submission.

Supplementary Information

Supplementary Material 1

Acknowledgements

We would like to thank Miss Panumas Kamkeng, Miss Tanyaporn Keratibumrungpong, and Mr. Tawatchai Chumponsuk of Metabolic Disease in Gastrointestinal and Urinary System Research Unit, staff of Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, and staff of the Animal Center, Faculty of Medicine, Chulalongkorn University and ModGut Co.Ltd for their generous help.

Author contributions

T.D. Conceptualization; M.U., M.S., T.D. Methodology; S.H., Validation; S.H., N.C., T.D. Formal analysis; S.H., W.A., M.T., T.D. Investigation; M.U., T.D. Resources; S.H. Data curation; S.H. Writing original draft preparation; T.D. Review and editing; S.H., N.C, T.D. Visualization; M.U., M.S., P.T., P.R., N.C., T.D. Supervision. T.D. Project administration; T.D. Funding acquisition. All authors reviewed the manuscript.

Data availability

The 16 S rRNA sequences of fecal from humans and rats generated and/or analysed during the current study are available in the NCBI BioProject repository, ID PRJNA1139982.

Declarations

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Tzelves L Türk C Skolarikos A European association of urology urolithiasis guidelines: Where are we going? Eur. Urol. Focus 2021 7 34 38 10.1016/j.euf.2020.09.011 33011151
Tzelves, L., Türk, C. & Skolarikos, A. European association of urology urolithiasis guidelines: Where are we going? Eur. Urol. Focus 7, 34–38. 10.1016/j.euf.2020.09.011 (2021).33011151
2. Li S Trends in the incidence and DALYs of urolithiasis from 1990 to 2019: Results from the global burden of disease study 2019 Front. Public. Health 2022 10 825541 10.3389/fpubh.2022.825541 35309229
Li, S. et al. Trends in the incidence and DALYs of urolithiasis from 1990 to 2019: Results from the global burden of disease study 2019. Front. Public. Health 10, 825541. 10.3389/fpubh.2022.825541 (2022).35309229
3. Xu Z Yao X Duan C Liu H Xu H Metabolic changes in kidney stone disease Front. Immunol. 2023 14 1142207 10.3389/fimmu.2023.1142207 37228601
Xu, Z., Yao, X., Duan, C., Liu, H. & Xu, H. Metabolic changes in kidney stone disease. Front. Immunol. 14, 1142207. 10.3389/fimmu.2023.1142207 (2023).37228601
4. Crivelli JJ Contribution of dietary oxalate and oxalate precursors to urinary oxalate excretion Nutrients 2023 10.3390/nu13010062
Crivelli, J. J. et al. Contribution of dietary oxalate and oxalate precursors to urinary oxalate excretion. Nutrients10.3390/nu13010062 (2020).
5. Pence S Low Oxalobacter formigenes colonization is associated with reduced bone mineral density in urinary stone forming patients Curr. Urol. 2015 8 189 193 10.1159/000365715 30263025
Pence, S. et al. Low Oxalobacter formigenes colonization is associated with reduced bone mineral density in urinary stone forming patients. Curr. Urol. 8, 189–193. 10.1159/000365715 (2015).30263025
6. Batislam E Yilmaz E Yuvanc E Kisa O Kisa U Quantitative analysis of colonization with real-time PCR to identify the role of Oxalobacter formigenes in calcium oxalate urolithiasis Urol. Res. 2012 40 455 460 10.1007/s00240-011-0449-8 22215293
Batislam, E., Yilmaz, E., Yuvanc, E., Kisa, O. & Kisa, U. Quantitative analysis of colonization with real-time PCR to identify the role of oxalobacter formigenes in calcium oxalate urolithiasis. Urol. Res. 40, 455–460. 10.1007/s00240-011-0449-8 (2012).22215293
7. Verhulst A Dehmel B Lindner E Akerman ME D’Haese PC Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition Urolithiasis 2022 50 119 130 10.1007/s00240-022-01310-9 35122487
Verhulst, A., Dehmel, B., Lindner, E., Akerman, M. E. & D’Haese, P. C. Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition. Urolithiasis 50, 119–130. 10.1007/s00240-022-01310-9 (2022).35122487
8. Chmiel JA New perspectives on an old grouping: The genomic and phenotypic variability of Oxalobacter formigenes and the implications for calcium oxalate stone prevention Front. Microbiol. 2022 13 1011102 10.3389/fmicb.2022.1011102 36620050
Chmiel, J. A. et al. New perspectives on an old grouping: The genomic and phenotypic variability of Oxalobacter formigenes and the implications for calcium oxalate stone prevention. Front. Microbiol. 13, 1011102. 10.3389/fmicb.2022.1011102 (2022).36620050
9. Kachroo N Meta-analysis of clinical microbiome studies in urolithiasis reveal age, stone composition, and study location as the predominant factors in urolithiasis-associated microbiome composition mBio 2021 12 e0200721 10.1128/mBio.02007-21 34372696
Kachroo, N. et al. Meta-analysis of clinical microbiome studies in urolithiasis reveal age, stone composition, and study location as the predominant factors in urolithiasis-associated microbiome composition. mBio 12, e0200721. 10.1128/mBio.02007-21 (2021).34372696
10. Ariceta G ePHex: A phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria Pediatr. Nephrol. 2023 38 403 415 10.1007/s00467-022-05591-5 35552824
Ariceta, G. et al. ePHex: A phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria. Pediatr. Nephrol. 38, 403–415. 10.1007/s00467-022-05591-5 (2023).35552824
11. Miller AW Dearing D The metabolic and ecological interactions of oxalate-degrading bacteria in the mammalian gut Pathogens 2013 2 636 652 10.3390/pathogens2040636 25437337
Miller, A. W. & Dearing, D. The metabolic and ecological interactions of oxalate-degrading bacteria in the mammalian gut. Pathogens 2, 636–652. 10.3390/pathogens2040636 (2013).25437337
12. Wigner P Bijak M Saluk-Bijak J Probiotics in the prevention of the calcium oxalate urolithiasis Cells 2013 10.3390/cells11020284
Wigner, P., Bijak, M. & Saluk-Bijak, J. Probiotics in the prevention of the calcium oxalate urolithiasis. Cells (2022). 10.3390/cells11020284
13. Stern JM Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers Urolithiasis 2016 44 399 407 10.1007/s00240-016-0882-9 27115405
Stern, J. M. et al. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers. Urolithiasis 44, 399–407. 10.1007/s00240-016-0882-9 (2016).27115405
14. Yuan T Gut microbiota in patients with kidney stones: A systematic review and meta-analysis BMC Microbiol. 2023 23 143 10.1186/s12866-023-02891-0 37208622
Yuan, T. et al. Gut microbiota in patients with kidney stones: A systematic review and meta-analysis. BMC Microbiol. 23, 143. 10.1186/s12866-023-02891-0 (2023).37208622
15. Stern JM Fecal transplant modifies urine chemistry risk factors for urinary stone disease Physiol. Rep. 2019 7 e14012 10.14814/phy2.14012 30789675
Stern, J. M. et al. Fecal transplant modifies urine chemistry risk factors for urinary stone disease. Physiol. Rep. 7, e14012. 10.14814/phy2.14012 (2019).30789675
16. Tiselius HG Aspects on estimation of the risk of calcium oxalate crystallization in urine Urol. Int. 1991 47 255 259 10.1159/000282232 1781112
Tiselius, H. G. Aspects on estimation of the risk of calcium oxalate crystallization in urine. Urol. Int. 47, 255–259. 10.1159/000282232 (1991).1781112
17. Bokoliya SC Dorsett Y Panier H Zhou Y Procedures for fecal microbiota transplantation in murine microbiome studies Front. Cell. Infect. Microbiol. 2021 11 711055 10.3389/fcimb.2021.711055 34621688
Bokoliya, S. C., Dorsett, Y., Panier, H. & Zhou, Y. Procedures for fecal microbiota transplantation in murine microbiome studies. Front. Cell. Infect. Microbiol. 11, 711055. 10.3389/fcimb.2021.711055 (2021).34621688
18. Ma S Wang N Zhang P Wu W Fu L Fecal microbiota transplantation mitigates bone loss by improving gut microbiome composition and gut barrier function in aged rats PeerJ 2021 9 e12293 10.7717/peerj.12293 34721980
Ma, S., Wang, N., Zhang, P., Wu, W. & Fu, L. Fecal microbiota transplantation mitigates bone loss by improving gut microbiome composition and gut barrier function in aged rats. PeerJ 9, e12293. 10.7717/peerj.12293 (2021).34721980
19. Schmidt EKA Fecal transplant prevents gut dysbiosis and anxiety-like behaviour after spinal cord injury in rats PLoS One 2020 15 e0226128 10.1371/journal.pone.0226128 31940312
Schmidt, E. K. A. et al. Fecal transplant prevents gut dysbiosis and anxiety-like behaviour after spinal cord injury in rats. PLoS One 15, e0226128. 10.1371/journal.pone.0226128 (2020).31940312
20. Tiselius HG Ferraz RR Heilberg IP An approximate estimate of the ion-activity product of calcium oxalate in rat urine Urol. Res. 2003 31 410 413 10.1007/s00240-003-0363-9 14579106
Tiselius, H. G., Ferraz, R. R. & Heilberg, I. P. An approximate estimate of the ion-activity product of calcium oxalate in rat urine. Urol. Res. 31, 410–413. 10.1007/s00240-003-0363-9 (2003).14579106
21. Yamaguchi S Study of a rat model for calcium oxalate crystal formation without severe renal damage in selected conditions Int. J. Urol. 2005 12 290 298 10.1111/j.1442-2042.2005.01038.x 15828958
Yamaguchi, S. et al. Study of a rat model for calcium oxalate crystal formation without severe renal damage in selected conditions. Int. J. Urol. 12, 290–298. 10.1111/j.1442-2042.2005.01038.x (2005).15828958
22. Vaziri ND Disintegration of colonic epithelial tight junction in uremia: A likely cause of CKD-associated inflammation Nephrol. Dial Transpl. 2012 27 2686 2693 10.1093/ndt/gfr624
Vaziri, N. D. et al. Disintegration of colonic epithelial tight junction in uremia: A likely cause of CKD-associated inflammation. Nephrol. Dial Transpl. 27, 2686–2693. 10.1093/ndt/gfr624 (2012).
23. Li H Increased oxidative stress and disrupted small intestinal tight junctions in cigarette smoke-exposed rats Mol. Med. Rep. 2015 11 4639 4644 10.3892/mmr.2015.3234 25606848
Li, H. et al. Increased oxidative stress and disrupted small intestinal tight junctions in cigarette smoke-exposed rats. Mol. Med. Rep. 11, 4639–4644. 10.3892/mmr.2015.3234 (2015).25606848
24. Liu Y Short-chain fatty acids reduced renal calcium oxalate stones by regulating the expression of intestinal oxalate transporter SLC26A6 mSystems 2021 6 e0104521 10.1128/mSystems.01045-21 34783577
Liu, Y. et al. Short-chain fatty acids reduced renal calcium oxalate stones by regulating the expression of intestinal oxalate transporter SLC26A6. mSystems 6, e0104521. 10.1128/mSystems.01045-21 (2021).34783577
25. Miri S Rasooli A Brar SK Data on changes of NF-κB gene expression in liver and lungs as a biomarker and hepatic injury in CLP-induced septic rats Data Brief 2019 25 104117 10.1016/j.dib.2019.104117 31428666
Miri, S., Rasooli, A. & Brar, S. K. Data on changes of NF-κB gene expression in liver and lungs as a biomarker and hepatic injury in CLP-induced septic rats. Data Brief 25, 104117. 10.1016/j.dib.2019.104117 (2019).31428666
26. Gombedza FC Shin S Sadiua J Stackhouse GB Bandyopadhyay BC The rise in tubular pH during hypercalciuria exacerbates calcium stone formation Int. J. Mol. Sci. 2024 10.3390/ijms25094787 38732005
Gombedza, F. C., Shin, S., Sadiua, J., Stackhouse, G. B. & Bandyopadhyay, B. C. The rise in tubular pH during hypercalciuria exacerbates calcium stone formation. Int. J. Mol. Sci.10.3390/ijms25094787 (2024).38732005
27. Baltazar P Oxalate (dys)metabolism: Person-to-person variability, kidney and cardiometabolic toxicity Genes (Basel) 2023 10.3390/genes14091719 37761859
Baltazar, P. et al. Oxalate (dys)metabolism: Person-to-person variability, kidney and cardiometabolic toxicity. Genes (Basel). 10.3390/genes14091719 (2023).37761859
28. Allam-Ndoul B Castonguay-Paradis S Veilleux A Gut microbiota and intestinal trans-epithelial permeability Int. J. Mol. Sci. 2020 10.3390/ijms21176402 32899147
Allam-Ndoul, B., Castonguay-Paradis, S. & Veilleux, A. Gut microbiota and intestinal trans-epithelial permeability. Int. J. Mol. Sci.10.3390/ijms21176402 (2020).32899147
29. Mishra SP A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut Gut 2023 10.1136/gutjnl-2022-327365 36948576
Mishra, S. P. et al. A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut. Gut. 10.1136/gutjnl-2022-327365 (2023).36948576
30. Lukiw WJ Bacteroides fragilis lipopolysaccharide and inflammatory signaling in Alzheimer’s disease Front. Microbiol. 2016 7 1544 10.3389/fmicb.2016.01544 27725817
Lukiw, W. J. Bacteroides fragilis lipopolysaccharide and inflammatory signaling in Alzheimer’s disease. Front. Microbiol. 7, 1544. 10.3389/fmicb.2016.01544 (2016).27725817
31. Yoshida N A possible beneficial effect of Bacteroides on faecal lipopolysaccharide activity and cardiovascular diseases Sci. Rep. 2020 10 13009 10.1038/s41598-020-69983-z 32747669
Yoshida, N. et al. A possible beneficial effect of Bacteroides on faecal lipopolysaccharide activity and cardiovascular diseases. Sci. Rep. 10, 13009. 10.1038/s41598-020-69983-z (2020).32747669
32. Fei N Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease mBio 2020 10.1128/mBio.03263-19 33203754
Fei, N. et al. Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease. mBio (2020). 10.1128/mBio.03263-1933203754
33. Wang Z Renal and intestinal transport defects in Slc26a6-null mice Am. J. Physiol. Cell. Physiol. 2005 288 C957 965 10.1152/ajpcell.00505.2004 15574486
Wang, Z. et al. Renal and intestinal transport defects in Slc26a6-null mice. Am. J. Physiol. Cell. Physiol. 288, C957–965. 10.1152/ajpcell.00505.2004 (2005).15574486
34. Wang J Wang W Wang H Tuo B Physiological and pathological functions of SLC26A6 Front. Med. (Lausanne) 2020 7 618256 10.3389/fmed.2020.618256 33553213
Wang, J., Wang, W., Wang, H. & Tuo, B. Physiological and pathological functions of SLC26A6. Front. Med. (Lausanne) 7, 618256. 10.3389/fmed.2020.618256 (2020).33553213
35. Neumeier LI Enteric oxalate secretion mediated by Slc26a6 defends against hyperoxalemia in murine models of chronic kidney disease J. Am. Soc. Nephrol. 2020 31 1987 1995 10.1681/asn.2020010105 32660969
Neumeier, L. I. et al. Enteric oxalate secretion mediated by Slc26a6 defends against hyperoxalemia in murine models of chronic kidney disease. J. Am. Soc. Nephrol. 31, 1987–1995. 10.1681/asn.2020010105 (2020).32660969
36. Soleimani M The role of SLC26A6-mediated chloride/oxalate exchange in causing susceptibility to nephrolithiasis J. Physiol. 2008 586 1205 1206 10.1113/jphysiol.2007.150565 18310129
Soleimani, M. The role of SLC26A6-mediated chloride/oxalate exchange in causing susceptibility to nephrolithiasis. J. Physiol. 586, 1205–1206. 10.1113/jphysiol.2007.150565 (2008).18310129
37. Jiang Z Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6 Nat. Genet. 2006 38 474 478 10.1038/ng1762 16532010
Jiang, Z. et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat. Genet. 38, 474–478. 10.1038/ng1762 (2006).16532010
38. Wang Y Increased abundance of bacteria of the family Muribaculaceae achieved by fecal microbiome transplantation correlates with the inhibition of kidney calcium oxalate stone deposition in experimental rats Front. Cell. Infect. Microbiol. 2023 13 1145196 10.3389/fcimb.2023.1145196 37313343
Wang, Y. et al. Increased abundance of bacteria of the family Muribaculaceae achieved by fecal microbiome transplantation correlates with the inhibition of kidney calcium oxalate stone deposition in experimental rats. Front. Cell. Infect. Microbiol. 13, 1145196. 10.3389/fcimb.2023.1145196 (2023).37313343
39. Parada Venegas D Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases Front. Immunol. 2019 10 277 10.3389/fimmu.2019.00277 30915065
Parada Venegas, D. et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol. 10, 277. 10.3389/fimmu.2019.00277 (2019).30915065
40. Smith BJ Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice BMC Microbiol. 2019 19 130 10.1186/s12866-019-1494-7 31195972
Smith, B. J. et al. Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice. BMC Microbiol. 19, 130. 10.1186/s12866-019-1494-7 (2019).31195972
